Assessment of sexual difficulties associated with multi-modal treatment for cervical or endometrial cancer: A systematic review of measurement instruments

White, Isabel; Sangha, Amrit; Lucas, Grace; Wiseman, Theresa

doi:10.1016/j.ygyno.2016.08.332

Cited by 22 publications

(25 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Baseline or pretransplantation depression, lack of desire, body image distortion, and anatomical damage are salient issues for patients after HSCT [20]. FSFI is the most used sexual function outcome measure, for research or clinical use, in healthy sexually active women [8], but also in subjects treated for breast [10], cervical [21,22], endometrial [22], and ovarian cancer [23]. FSFI had been used as a measure of sexual function in cohort of subjects after HSCT, including adult women with 6.5-year-median time elapsed from cancer diagnosis [24].…”

Section: Discussionmentioning

confidence: 99%

Vaginal development and sexual functioning in young women after stem cell transplantation, chemotherapy, and/or radiotherapy for childhood hematological diseases

Beneventi

Locatelli

Simonetta

et al. 2018

Bone Marrow Transplant

View full text Add to dashboard Cite

To study vaginal development and sexual functioning in young women after childhood hemopoietic stem cell transplantation (HSCT) and radio/chemotherapy. Observational case-control study on 30 young sexually active women survived after HSCT and/or radio/chemotherapy for childhood malignancies or hematologic diseases and 48 controls matched for age. Female Sexual Function Index was lower (median 24.05, IQR = 17.30-28.30 vs. 29.00, IQR = 25.30-31.40, p = 0.001), Female Sexual Distress Scale higher (median 16.00, IQR = 8.00-23.00 vs. 2.00, IQR = 0.00-4.00, p < 0.001), vaginal length shorter (mean difference = 21.1 mm; 95% CI = 19.3-23, p < .001) and vaginal maturation index worst in cases than in controls. Subjects treated by irradiation before HSCT had lower FSFI (median 21.85, IQR = 9.60-31.10 vs. 24.90, IQR = 17.30-28.30) and shorter vaginal length (median 45.55, IQR = 42.60-45.80 vs. 50.10, IQR = 45.30-52.90) compared to those who had not received conditioning treatment (p-values = 0.004 and p = 0.05, respectively). Compared to untreated subjects, women receiving hormonal replacement therapy had higher overall FSFI (p = 0.02), lower FSDS (0.04), and better VMI. Gonadotoxic therapies have adverse effects on vaginal development, sexual functioning, and distress in young females. Hormonal replacement therapy should be shortly considered after main gonodatoxic treatments to improve vaginal and sex health.

show abstract

Section: Discussionmentioning

confidence: 99%

Vaginal development and sexual functioning in young women after stem cell transplantation, chemotherapy, and/or radiotherapy for childhood hematological diseases

Beneventi

Locatelli

Simonetta

et al. 2018

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Sexual function was measured by the Greek version of the Female Sexual Function Index (FSFI) ( 29 ), a 19-item multiple choice questionnaire, which we have used in previous research ( 30 , 31 , 32 ). The FSFI is an internationally accepted and reliable instrument for rating female sexual function for research or clinical use ( 33 ). It measures six domains, including sexual desire, arousal (subjective), lubrication, orgasm, satisfaction and pain over the past 4 weeks.…”

Section: Methodsmentioning

confidence: 99%

Impact of estrogen receptor α gene and oxytocin receptor gene polymorphisms on female sexuality

Armeni

Assimakopoulos

Marioli

et al. 2017

Endocrine Connections

View full text Add to dashboard Cite

Over the past decades, research attention has increasingly been paid to the neurobiological component of sexual behavior. The aim of the present study was to investigate the correlation of estrogen receptor α (ERA) gene polymorphism (rs2234693-PvuII) (T→C substitution) and oxytocin receptor gene polymorphism (rs53576) (G→A substitution) with sexuality parameters of young, healthy women. One hundred thirty-three Greek heterosexual women, students in higher education institutions, 20–25 years of age, sexually active, with normal menstrual cycles (28–35 days), were recruited in the study. Exclusion criteria were chronic and/or major psychiatric diseases, use of oral contraceptive pills (OCs), polycystic ovary syndrome (PCOS), thyroid diseases as well as drugs that are implicated in hypothalamus–pituitary–gonadal axis. T allele (wildtype) of rs2234693 (PvuII) polymorphism of ERA gene was correlated with increased levels of arousal and lubrication, whereas A allele (polymorphic) of rs53576 (OXTR) polymorphism was correlated with increased arousal levels. The simultaneous presence of both T allele of rs2234693 (PvuII) and A allele of rs53576 (OXTR) polymorphisms (T + A group) was correlated with increased arousal, orgasm levels as well as female sexual function index full score. To our knowledge, this is the first study to investigate the interaction between ERA and OXTR with regard to sexual function in women. Female sexuality is a complex behavioral trait that encompasses both biological and psychological components. It seems that variability in female sexual response stems from genetic variability that characterizes endocrine, neurotransmitter and central nervous system influences.

show abstract

“…This may not occur if the ovaries are transposed. When compared with surgery alone, primary or adjuvant radiation therapy has been associated with greater sexual dysfunction and vaginal toxicity, such as stenosis, shortening, atrophy and fibrosis [14].…”

Section: Cervical Cancermentioning

confidence: 99%

“…Longer survival times and potential treatment-related morbidity have led to a greater emphasis being placed on other criteria in addition to survival in trial outcomes. There are several instruments used to measure sexual function in women and they also aim to help patients highlight concerns of a sensitive nature that are often not directly discussed by clinicians [20]. Several questionnaires exist specifically for female survivors, although none of these has been validated for routine use [21].…”

Section: Evaluation and Assessment Of Sexual Health In The Gynaecological Cancer Survivormentioning

confidence: 99%

Sexual and Psychosexual Consequences of Treatment for Gynaecological Cancers

2021

View full text Add to dashboard Cite

Assessment of sexual difficulties associated with multi-modal treatment for cervical or endometrial cancer: A systematic review of measurement instruments

Cited by 22 publications

References 58 publications

Vaginal development and sexual functioning in young women after stem cell transplantation, chemotherapy, and/or radiotherapy for childhood hematological diseases

Vaginal development and sexual functioning in young women after stem cell transplantation, chemotherapy, and/or radiotherapy for childhood hematological diseases

Impact of estrogen receptor α gene and oxytocin receptor gene polymorphisms on female sexuality

Sexual and Psychosexual Consequences of Treatment for Gynaecological Cancers

Contact Info

Product

Resources

About